据了解，该仓储和物流中心依据《上海市药品现代物流指导意见》的要求建成，集成了2℃-8℃冷藏 库、15℃-25℃温控库等多温区仓储系统，并配备楼宇管理系统、环境温湿度监视系统及仓库自动化控 制系统，具备保税和非保税功能，将进一步强化诺和诺德在中国供应链的灵活性与韧性。 在采访中，记者了解到，该仓储和物流中心也是诺和诺德中国开放创新中心的四大支柱内容之一。在中 国，诺和诺德的创新合作伙伴已从最初的基础和转化研究与临床开发，扩展到数字化健康生态联盟以及 仓储物流分销等多个领域。为进一步提升现有的创新与合作水平，诺和诺德成立诺和诺德中国开放创新 中心，通过与多方合作，构建开放融合的创新生态，为中国医药创新生态系统持续注入动能。今年5 月，诺和诺德中国开放创新中心获上海浦东新区政府正式授牌，加入浦东新区"大企业开放创新中心 (Group Open Innovation Center，简称GOI)"计划。 植根中国31年，诺和诺德已将22款创新药和11款创新注射装置引进中国。如今，诺和诺德正以上海为支 点之一，持续书写与中国市场双向奔赴的精彩篇章。随着上海仓储和物流中心的全面启用，诺和诺德将 "在上海，我们感受到的是开放 ...

Core Viewpoint - Novo Nordisk has received approval from the National Medical Products Administration (NMPA) for its drug, Ozempic® (semaglutide injection), to be used for a new indication in chronic kidney disease (CKD) [1] Group 1: Company Developments - Novo Nordisk's Ozempic® is now the first and only GLP-1 receptor agonist (GLP-1RA) approved in China for reducing the risk of sustained decline in eGFR, end-stage kidney disease, and cardiovascular death in adult patients with type 2 diabetes and CKD [1]

Core Insights - Ark Health has launched Novo Nordisk's innovative diabetes medications, including the injectable Semaglutide (Nuohe Tai®) and oral Semaglutide (Nuohe Xin®), aiming to provide effective treatment for a broader range of adult type 2 diabetes patients [1] Group 1: Product Launch and Features - Nuohe Tai® is a GLP-1 receptor agonist that has been well-received since its launch in China in 2021 due to its excellent glycemic control and convenient once-weekly dosing [1] - Nuohe Xin®, the world's first oral GLP-1 receptor agonist, was fully launched in China in January 2025, utilizing "SNAC absorption enhancer" technology to facilitate daily oral administration [1] Group 2: Market Context - China has the highest number of type 2 diabetes patients globally, with approximately 148 million patients aged 20-79, accounting for over a quarter of the world's total [1] - The prevalence of overweight/obesity, dyslipidemia, and hypertension is notably high among these patients, indicating a significant health need [1] Group 3: Future Strategy - The company plans to continue integrating digital intelligence with internet healthcare services, establishing strategic partnerships with leading biopharmaceutical companies to create a new landscape for smart healthcare [2] - The goal is to transform cutting-edge medical research into accessible chronic disease management solutions, enhancing service quality for chronic disease patients [2]